2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …

TA McDonagh, M Metra, M Adamo… - European heart …, 2021 - academic.oup.com
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement

J Herrmann, D Lenihan, S Armenian… - European heart …, 2022 - academic.oup.com
Abstract The discipline of Cardio-Oncology has seen tremendous growth over the past
decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the …

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …

AR Lyon, T López-Fernández, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …

Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial

TG Neilan, T Quinaglia, T Onoue, SS Mahmood… - JAMA, 2023 - jamanetwork.com
Importance Anthracyclines treat a broad range of cancers. Basic and retrospective clinical
data have suggested that use of atorvastatin may be associated with a reduction in cardiac …

The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review

T Omland, SL Heck, G Gulati - Cardio Oncology, 2022 - jacc.org
Cardiotoxicity is a relatively frequent and potentially serious side effect of traditional and
targeted cancer therapies. Both general measures and specific pharmacologic …

Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies

N Dempsey, A Rosenthal, N Dabas… - Breast Cancer Research …, 2021 - Springer
Purpose Despite great success as a targeted breast cancer therapy, trastuzumab use may
be complicated by heart failure and loss of left ventricular contractile function. This review …

Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica

SE de Cardiología, Heart Failure Association - 2021 - dspace.uniandes.edu.ec
Las guías de práctica clínica (GPC) tienen como objetivo reunir y evaluar toda la evidencia
relevante disponible durante el proceso de elaboración sobre un tema particular para …

Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review

LA Baldassarre, S Ganatra, J Lopez-Mattei… - Journal of the American …, 2022 - jacc.org
The population of patients with cancer is rapidly expanding, and the diagnosis and
monitoring of cardiovascular complications greatly rely on imaging. Numerous advances in …

Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy: 3-year results of the SUCCOUR trial

T Negishi, P Thavendiranathan, M Penicka… - Cardiovascular …, 2023 - jacc.org
Background Global longitudinal strain (GLS) can predict cancer therapeutics–related
cardiac dysfunction and guide initiation of cardioprotection (CPT). Objectives In this study …